A number of drugs are in development for the treatment of <i>ERBB2</i>(<i>HER2</i>)-mutated NSCLC, including antibody-drug conjugates such as trastuzumab-deruxtecan and tyrosine kinase inhibitors such as zongertinib and sevabertinib. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.